Medicare Part D
The prescription drug insurance benefit for the elderly added to Medicare under President George W. Bush, which Kotlikoff says added roughly $15 trillion to the fiscal gap.
As defined in Laurence Kotlikoff on Debt, Default, and the Federal Government's Finances
Where it comes up · 3
- Vincent Rajkumar on the High Price of Cancer Drugs5 claims
- Laurence Kotlikoff on Debt, Default, and the Federal Government's Finances1 claim
- Mark Cuban1 claim
Most important claims · 7 of 7Search all claims for “Medicare Part D” →
- The big three PBMs reimburse community pharmacies less than their net cost for brand drugs (e.g. reimbursing $500 or less on a drug with $550 net investment), especially under Medicare Part D and Advantage, making the government complicit in driving tens of thousands of independent pharmacies out of business — which in turn motivates big-brand manufacturers to work with Cost Plus to support independents and break the cartel's vertical integration.Mark Cuban
- The fiscal problem is fundamentally a conflict between adults and children rather than right versus left or rich versus poor, because both parties have run 'take-as-you-go' policies in which each generation extracts from the young; Medicare Part D, for example, added roughly $15 trillion to the fiscal gap without asking a single elderly person to pay a penny, dumping the bill on future children—an arrangement Kotlikoff calls generational theft.Laurence Kotlikoff on Debt, Default, and the Federal Government's Finances
- Pharmaceutical companies are not to be blamed because they are simply following the incentives that have been put in place; given that they can avoid innovating and just raise prices yearly to meet targets, their behavior is unsurprising, though the crony side is that industry influenced the midnight passage of the Medicare Part D law.Vincent Rajkumar on the High Price of Cancer Drugs
- Because insurance or Medicare pays rather than individuals, normal market forces are absent and drug prices rise to the level the whole of society can bear rather than what individuals can afford out of pocket; in countries like India where care is out-of-pocket, patients simply cannot buy unaffordable drugs, so prices reflect what people can actually pay.Vincent Rajkumar on the High Price of Cancer Drugs
- A 65-year-old myeloma patient can extend life from 3-4 years to roughly 6-8 years, but doing so costs on the order of three-quarters of a million dollars or more in the United States, almost always paid by Medicare or insurers rather than the patient.Vincent Rajkumar on the High Price of Cancer Drugs
- The single most important reform, endorsed across the industry at an HHS forum, is to change the law so Medicare can negotiate drug prices on behalf of its citizens, with safeguards and a value benchmark—such as paying $50,000-$150,000 for a drug that adds a year of life—since the bargaining power of so large a buyer cannot be overestimated and most countries already do this.Vincent Rajkumar on the High Price of Cancer Drugs
- U.S. law requires Medicare to buy and provide Part D drugs for its citizens while forbidding it from negotiating the price, so it must pay whatever the pharmaceutical company says the drug is worth; from the point that law passed, drug costs rose faster than before, a design flaw that benefits the industry.Vincent Rajkumar on the High Price of Cancer Drugs